CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus
The CYP2C19 gene type does not appear to increase the risk of developing systemic lupus erythematosus (SLE), an autoimmune connective tissue disorder. The particular gene type, associated with cytochrome P450, reduces the ability of the body to metabolize certain drugs. SLE sometimes develops after exposure to particular drugs or chemicals. Researchers gave the drug mephenytoin to 37 SLE patients and 161 healthy people, then measured drug metabolites in their urine. Genetic examination of blood samples indicated that the CYP2C19 gene type was not more common among SLE patients, and the ratio of drug metabolites in the urine samples failed to show an association between the gene type and SLE.
Publication Name: Annals of the Rheumatic Diseases
Paradoxical effect of prostacyclin infusion in a patient with primary pulmonary hypertension: A case report
The paradoxical effect of prostacyclin treatment in a patient with primary pulmonary hypertension is presented by a case report. This case report shows an increase in pulmonary artery pressure in the patient when treated with prostacyclin infusion.
Publication Name: Angiology
- Abstracts: Antibodies to DNA. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus
- Abstracts: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. Multidisciplinary management of lung cancer
- Abstracts: Limitations in the interpretation of biopsies in patients with penile squamous cell carcinoma. Pleomorphic rhabdomyosarcoma of the anterior abdominal wall following multimodality treatment for carcinoma of the rectum
- Abstracts: Alveolar adenoma of the lung: a clinicopathologic, immunohistochemical, and molecular study of an unusual case
- Abstracts: Patient perceptions of breast biopsy procedures for screen-detected lesions. Exercise and bone mineral density at the femoral neck in postmenopausal women: A meta-analysis of controlled clinical trials with individual patient data